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Abstract
Background
Seasonal malaria chemoprevention (SMC) is recommended in the Sahel region of Africa for
children under 5 years of age, for up to 4 months of the year. It may be appropriate to include
older children, and to provide protection for more than 4 months. We evaluated the effective-
ness of SMC using sulfadoxine-pyrimethamine plus amodiaquine given over 5 months to
children under 10 years of age in Saraya district in south-east Senegal in 2011.
Methods and findings
Twenty-four villages, including 2,301 children aged 3–59 months and 2,245 aged 5–9 years,
were randomised to receive SMC with community case management (CCM) (SMC villages)
or CCM alone (control villages). In all villages, community health workers (CHWs) were
trained to treat malaria cases with artemisinin combination therapy after testing with a rapid
diagnostic test (RDT). In SMC villages, CHWs administered SMC to children aged 3 months
to 9 years once a month for 5 months. The study was conducted from 27 July to 31 Decem-
ber 2011. The primary outcome was malaria (fever or history of fever with a positive RDT).
The prevalence of anaemia and parasitaemia was measured in a survey at the end of the
transmission season. Molecular markers associated with resistance to SMC drugs were
analysed in samples from incident malaria cases and from children with parasitaemia in the
survey. SMC was well tolerated with no serious adverse reactions. There were 1,472 RDT-
confirmed malaria cases in the control villages and 270 in the SMC villages. Among children
under 5 years of age, the rate difference was 110.8/1,000/month (95% CI 64.7, 156.8; p <
0.001) and among children 5–9 years of age, 101.3/1,000/month (95% CI 66.7, 136.0; p <
0.001). The mean haemoglobin concentration at the end of the transmission season was
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higher in SMC than control villages, by 6.5 g/l (95% CI 2.0, 11; p = 0.007) among children
under 5 years of age, and by 5.2 g/l (95% CI 0.4, 9.9; p = 0.035) among children 5–9 years
of age. The prevalence of parasitaemia was 18% in children under 5 years of age and 25%
in children 5–9 years of age in the control villages, and 5.7% and 5.8%, respectively, in
these 2 age groups in the SMC villages, with prevalence differences of 12.5% (95% CI
6.8%, 18.2%; p < 0.001) in children under 5 years of age and 19.3% (95% CI 8.3%, 30.2%;
p < 0.001) in children 5–9 years of age. The pfdhps-540E mutation associated with clinical
resistance to sulfadoxine-pyrimethamine was found in 0.8% of samples from malaria cases
but not in the final survey. Twelve children died in the control group and 14 in the SMC
group, a rate difference of 0.096/1,000 child-months (95% CI 0.99, 1.18; p = 0.895). Limita-
tions of this study include that we were not able to obtain blood smears for microscopy for all
suspected malaria cases, such that we had to rely on RDTs for confirmation, which may
have included false positives.
Conclusions
In this study SMC for children under 10 years of age given over 5 months was feasible, well
tolerated, and effective in preventing malaria episodes, and reduced the prevalence of para-
sitaemia and anaemia. SMC with CCM achieved high coverage and ensured children with
malaria were promptly treated with artemether-lumefantrine.
Trial registration
www.clinicaltrials.gov NCT01449045.
Author summary
Why was this study done?
• Seasonal malaria chemoprevention (SMC) is recommended for children under 5 years
of age for up to 4 months of the year in the Sahel and sub-Sahel, but could be useful in
older children and in areas with a longer transmission season.
• This study was done in south-east Senegal—where the main malaria transmission sea-
son lasts for 5 months and there is a high burden of malaria in the under-10 age group
—to determine the effectiveness of SMC delivered for 5 months to children under 10
years of age by community health workers (CHWs) who were also providing commu-
nity case management for malaria.
What did the researchers do and find?
• Twenty-four villages that had a resident CHW providing community case management
for malaria were randomised: In 12 of the villages the CHW was trained to administer
SMC once a month for 5 months during the transmission season to all children aged
between 3 months and 10 years, while the other 12 villages did not have SMC.
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• Malaria cases confirmed by rapid diagnostic test (RDT) were recorded by the CHWs. At
the end of the transmission season, children were surveyed to measure their haemoglo-
bin concentration and to check for the presence of malaria parasites.
• SMC was associated with 111 fewer malaria cases per 1,000 children per month in chil-
dren under 5 years of age and 101 fewer cases per 1,000 children per month in children
aged 5–9 years as compared with community case management alone.
• SMC was associated with a reduction in the percentage of children (in both age groups)
with anaemia at the end of the transmission season of 18%, and a reduction in the per-
centage of children with malaria parasitaemia of 73%, compared to community case
management alone.
• The study did not find a reduction in mortality and did not measure the impact of SMC
on severe malaria.
What do these findings mean?
• SMC can be administered effectively for 5 months in children up to the age of 10 years,
the treatments are well tolerated, and high coverage can be achieved.
• Twelve countries now have SMC programmes, with SMC provided for 3 or 4 months to
children under 5 years of age (with the exception of Senegal, where children under 10
years are included). The findings of this study indicate that SMC could be administered
over a longer period and/or to a wider age group. The strategy could be adapted depend-
ing on local epidemiology, to increase the impact on malaria.
Introduction
Seasonal malaria chemoprevention (SMC), the administration once per month of antimalarial
treatment using sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) to prevent malaria, is
currently recommended in the Sahel region of Africa for children under 5 years of age, for up to 4
months of the year [1]. In many of parts of this region, it may be appropriate to consider extend-
ing the scope of SMC programmes by including older children [2–6] and, in areas with a longer
transmission season, by providing protection for more than 4 months each year. In south-east
Senegal, for example, individual patient data from Saraya Hospital extracted from registers for the
year 2011 showed that 75% of cases admitted to hospital with severe malaria were children under
10 years of age, and 85% of the severe malaria cases occurred over the 5 months from July to
November (Fig 1). In addition, in remote areas, it may be beneficial to combine SMC with com-
munity case management (CCM) [7] or to provide SMC teams with access to rapid diagnostic
tests (RDTs) and artemisinin combination therapies (ACTs) so that children who are unwell can
be screened quickly and treated with rapid-acting ACTs if they are shown to have malaria.
To guide SMC policy in Senegal, we undertook a cluster randomised trial to evaluate the
effectiveness of SMC in children under 10 years of age, extended over 5 months, in a high-
transmission area in the south-east of the country. The study was done in villages where CCM
for malaria (PECADOM, prise en charge à domicile) had been established, in order to assess
the added benefit of combining SMC with PECADOM and the feasibility of both interventions
being delivered together.
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Methods
Study site
Saraya Department (district, Kedougou Region), in the south-east of Senegal, bordering Mali
to the east and Guinea to the south, is composed of the rural communities of Sabadola,
Fig 1. The age distribution and seasonal pattern of patient admissions to Saraya Hospital with malaria in 2011. The
number of patients admitted to Saraya Hospital with severe malaria in 2011, by month of admission (A) and by age (B).
Individual patient data (age, date of admission, and primary diagnosis) were extracted from the hospital registers for all
patients admitted from 1 January to 31 December 2011. (A) also shows a line indicating monthly rainfall (on the right-
hand axis). (C) shows the proportion of cases that could potentially have been prevented by seasonal malaria
chemoprevention (SMC), if SMC had been provided for children up to the age of 5 years or up to the age of 10 years, for
4 consecutive months or for 5 consecutive months starting on the date indicated. The y-axis shows the cases in 2011 in
the given age group that fell in a 4- or 5-month window starting from the given date, as a proportion of total cases. From
January to December there were a total of 195 admissions with severe malaria, 147 of them under 10 years of age, and of
those, 91/147 (62%) were under 5 years and 56 (38%) were 5–9 years of age. In all, 7/195 patients died, 1 aged 18 years
and the other 6 aged under 5 years. Ten of the 195 patients had cerebral malaria; all these patients were under 10 years of
age—7 of them under 5 years of age and 3 aged 5–9 years. In all, 165 (85%) of the 195 cases occurred in the 5 months
from July to November (rainfall data from Climate-Data.org).
https://doi.org/10.1371/journal.pmed.1002762.g001
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Khossanto, Bembou, Missirah Sirimana, and Medina Baffe, and includes 102 villages occupy-
ing a land area of 7,803 km2, with an estimated total population of 37,048 (2009 estimate).
Over 70% of the population live more than 15 km from a health facility. The main ethnic
groups are Malinke and Diakhanke. The climate is Sudano-Sahelian with 2 seasons, a dry sea-
son from November to May and a rainy season from May to November. Mean daily tempera-
tures range from 14˚C to 36˚C from July to February and 21˚C to 40˚C from March to June.
The malaria transmission season is longer than in other parts of Senegal, lasting about 6
months. This study took place in 24 rural villages in Saraya Department where PECADOM
had been established in 2009–2010: 12 villages where malaria case management was provided
(for patients of all ages) by a village volunteer (distributeur de soins à domicile [DSDOM]) who
can test for malaria with an RDT and treat with artemether-lumefantrine, and 12 villages with
a health hut (case de santé) managed by an agent de santé communautaire (ASC), equipped
with RDTs, artemether-lumefantrine, oral rehydration solution, zinc, and an antibiotic (amox-
icillin), who can treat diarrhoea, respiratory infection, and malaria. (In this paper we also use
the term community health worker [CHW] to refer to both DSDOMs and ASCs.) The study
population comprised all children aged from 3 months to 119 months living in these villages.
A map of the study area is shown in Fig 2.
Study design
Twenty-four villages, 12 where malaria case management was provided by a DSDOM and 12
with a case de santé managed by an ASC, were selected, forming 2 strata for randomisation
and analysis. A census of the study villages was undertaken in July 2011 by the 24 CHWs and
10 nurses from the health posts serving the area who were trained for this purpose. Children
who would be aged 3–119 months at the time scheduled for the first SMC treatment and who
had no known allergy to SMC drugs were eligible to participate. Cluster randomisation was
chosen to allow the overall impact of SMC, including any indirect effect on transmission, to be
captured, and to allow assessment of the impact of adding SMC on the overall workload of the
health workers. Randomisation in each stratum was constrained to ensure balanced allocation
with respect to population size, distance to the nearest health post or hospital, and the malaria
incidence in the village the year before the trial, and was performed using Stata version 11 (Sta-
taCorp, College Station, Texas) by a statistician at the London School of Hygiene & Tropical
Medicine. The number of permutations of 12 clusters in each of 2 strata is [12!/(6!6!)]2 =
853,776. One permutation was chosen from a total of 229 permutations that met the require-
ment that for each of the variables within each stratum the difference in the mean between the
2 groups should be less than 15% of the overall mean for that variable. The primary endpoint
was malaria defined as fever (axillary temperature� 37.5˚C) or a history of fever, with no obvi-
ous other cause of the fever, and a positive result for malaria by RDT. It was intended to use
microscopically confirmed cases for the primary analysis, but although CHWs were trained to
make blood films, it was not possible to obtain blood films for all suspected cases. RDT-con-
firmed malaria was therefore used for the primary analysis. The secondary endpoints were
coverage of SMC; parasitaemia, gametocyte carriage, haemoglobin (Hb) concentration, anae-
mia (Hb< 110 g/l), and severe anaemia (Hb < 60 g/l) at the end of the transmission season;
the presence of molecular markers of resistance to SP and AQ in samples from malaria cases
and in samples taken in the survey of children at the end of the transmission season; mortality
(any cause); and occurrence of adverse events at any time during the study period and within
10 days of each SMC administration, with an emphasis on skin rash, diarrhoea, vomiting, and
signs of jaundice/liver disease. Process indicators included the number of courses of SP and
AQ administered, the number of children treated each month, the number of person-days
Seasonal malaria chemoprevention plus community case management over 5 months in southern Senegal
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002762 March 13, 2019 5 / 24
spent by health workers on SMC delivery, the number of supervision visits made to the vil-
lages, the number of training sessions held, and the number of persons trained; these data will
be published in a separate report.
Ethics
Members of the study team held meetings with community, administrative, and religious lead-
ers to explain the aims and activities of the study and to seek community approval and pro-
mote community ownership of the programme. Staff then visited each household to explain
the study in the local language, provided an information sheet, and sought signed consent
Fig 2. Map of the study area showing the location of the study villages. SMC, seasonal malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1002762.g002
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from parents. Children whose parents consented were enrolled, and mothers/caregivers were
issued with an ID card bearing the details and study ID number for each eligible child in their
care. The ID card was used to identify children if malaria was diagnosed and, for those in clus-
ters randomised to receive SMC, to document SMC courses of treatment received. A data and
safety monitoring board was convened to oversee the project and review data on tolerability
and safety. The study was approved by the Comite´ National d’Ethique pour la Recherche en
Sante´ of Senegal. The National Director of Health gave administrative authorisation to con-
duct the study. Trial registration (ClinicalTrials.gov NCT01449045) was started on 5 July 2011,
but due to an administrative oversight was not completed until 11 September 2011; the trial
was posted on the ClinicalTrials.gov website on 6 October 2011.
Malaria surveillance
In each village, the PECADOM system supports a resident CHW to provide malaria case man-
agement. Persons with fever are encouraged to attend the health hut or the home of the health
worker to be tested with an RDT (Core Malaria Pf test, CORE Diagnostics, New Delhi, India)
and treated with artemether-lumefantrine if the test is positive. Consultations are recorded in
a register to document the test results and treatment given. Severe cases, children less than 2
months of age, and pregnant women are referred to the health post or district hospital. For this
study, refresher training in CHW roles was provided, and, in addition, the CHWs were trained
to prepare thick and thin blood films, which were collected by the trial team for microscopic
examination to crosscheck the RDT results. CHWs were also trained to take blood spots onto
filter paper for molecular analysis, and to record and report any adverse events. Nurses at
health posts and district hospitals were also trained to prepare thick and thin films.
If a child was unwell on the day of the SMC visit, caregivers were asked to bring the child to
the health hut or home of the DSDOM for testing with malaria RDT; those who tested positive
were treated with artemether-lumefantrine, and those who tested negative received SMC and
were then referred to the nearest health post.
Participants who presented at health posts or at the district hospital with fever were simi-
larly tested with an RDT and had thick and thin blood films taken by the nurse, which were
read later. Treatment of study participants seen at the health posts for other conditions was
carried out in accordance with national guidelines.
All positive RDTs were retained for subsequent DNA extraction.
Registers for recording SMC administration (in SMC villages) and morbidity (in all
study villages), with a list of all children enrolled in each village, were made available for
each CHW. In SMC villages, the dose of SP and AQ administered to each child was
recorded in the register. All consultations for illness were also recorded in the registers
(including date, symptoms, RDT result, and treatment). In addition, in each health post,
consultation records were reviewed by the nurse to identify all consultations of children
from the study villages.
Mortality surveillance
A reporter was appointed in each village to record deaths in children aged less than 10 years. A
verbal autopsy was performed by project staff using a questionnaire adapted from WHO and
the INDEPTH Network for children under the age of 12 years. Two physicians reviewed the
reports and coded the cause of death independently; any discrepancies were resolved by a
panel. In addition, in SMC villages, some deaths that had not been reported were detected
when the study team investigated children who were absent from SMC cycles.
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Community sensitisation
Social mobilisation was organised through local meetings before the start of SMC administra-
tion to explain when the campaign would start, how the treatments would be administered,
and the importance of adherence to the drug regimen. Local community radio and announce-
ments in the mosques were used to inform the community about the timing of SMC and to
emphasise the importance of ensuring children received treatment each month and adhered to
the regimen each month.
SMC administration
Training for CHWs was organised over 3 days to explain how to administer SMC, including
checking for fever and for any intake of SP or AQ or sulfa-containing antibiotics in the preced-
ing month, checking the child’s age and selecting the correct dose, administering SP and the
first dose of AQ, and explaining to the caregiver how to administer the remaining 2 doses of
AQ. CHWs went door to door from 7 AM in the morning and in the evenings, when children
and caregivers were most likely to be at home, starting cycles on Friday afternoon or Saturday
morning so as to be able to reach school-age children. Infants aged 3 to 11 months received 0.5
tablets of SP and 3× 0.5 tablets of AQ, children aged 1 to 5 years received 1 tablet of SP + 3× 1
tablet of AQ, and children aged 6 to 9 years received 1.5 tablets of SP + 3× 1.5 tablets of AQ.
This dosing schedule was selected to minimise under- and overdosing, based on weight-for-
age data from a survey in Niakhar [3], to keep simple age categories, and to avoid the use of
quarter tablets. Sweetened dispersible tablets of SP and AQ were used (SP: 500/25-mg tablets;
AQ: 153-mg tablets, both manufactured by Kinapharma, Accra, Ghana), mixed with water.
Household water and utensils were used for SMC administration. SMC administration was
conducted once a month for 5 months starting in July 2011. Each SMC cycle was planned to
last 3 to 5 days.
Surveillance of adverse events
Caregivers of study children were encouraged to bring children to the CHW if they were
unwell after SMC administration.
Monitoring of adherence
A survey was conducted during the fourth and the fifth SMC cycles, to ask caregivers about
adherence: 318 children were surveyed in 8 SMC villages during cycle 4, and 462 children in 3
SMC villages during cycle 5.
Supervision of SMC administration
Project staff (4 local supervisors and 2 project coordinators) visited each village 2 weeks after
each SMC cycle to collect data on SMC coverage, malaria cases, adverse events, and deaths; to
collect blood slides; and also to check drug supplies in order to prepare for the next adminis-
tration cycle.
Baseline census
A census was conducted in July 2011 by the CHW in each village to ask about household assets
(for assessment of socioeconomic status), level of education, and other characteristics of adults
in each household, and to record ownership and condition of bednets.
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Survey of the prevalence of parasitaemia and anaemia
A survey was conducted in each village at the end of the transmission season, in December—1
month after the last SMC cycle—to take a finger prick blood sample to make blood films for
measurement of Plasmodium falciparum parasitaemia and gametocyte carriage, to measure
Hb concentration using a hemocue machine (Hb301, HemoCue, A¨ngelholm, Sweden), and to
take blood spots on filter paper for molecular analysis of markers of resistance to SMC drugs.
This survey included 35 children in each age group (aged less than 5 years and 5–9 years) in
each village, by simple random sampling from the census list. A questionnaire was adminis-
tered to assess use of insecticide-treated bednets by study children; caregivers’ knowledge, atti-
tudes, and practices in relation to malaria; acceptability of SMC; and adherence to the
unsupervised AQ doses in the last SMC cycle.
Laboratory methods
Thick smears were stained with Giemsa stain and 200 high-power fields (HPFs) examined before
a smear was declared negative. Parasite density was expressed per microlitre with the assumption
that 1 parasite per HPF equals a density of 500 parasites per microlitre. Slides were read indepen-
dently by 2 laboratory technicians, who were unaware of which village the slides came from. If
there was disagreement between their readings on parasite positivity or if the difference in the
log10 densities recorded was more than 1.5, slides were read by a third technician. Discrepancies
occurred mainly in smears with very low parasite densities. A sample of tablets of SP and AQ
were tested at the Drug Quality Control National Laboratory in Dakar at the beginning and at the
end of the study for drug content and dissolution. At the end of the study, a further sample of AQ
tablets from the field was tested for drug content at the national laboratory in Dakar; drug content
was within 5% of the nominal level. For clinical cases, a sample of positive RDTs was selected
(130/270 from SMC villages and 110/1,472 from control villages) and parasite DNA was extracted
directly from the RDT cassette. For cross-sectional surveys, blood samples were collected on filter
paper. For both sample types, DNA was extracted by the Chelex method [8] and mutations in the
pfmdr1 gene (codons 86 and 184), pfdhfr gene (codons 51, 59, and 108), and pfdhps gene (codons
431, 436, 437, 540, 581, and 613) were typed.
Statistical methods
The study was designed to have at least 90% power to detect a reduction in the incidence of
malaria of 50% assuming an incidence rate of 0.04 per child per transmission season (i.e., 8 per
1,000 child-months, based on data from 2009 from district health records showing there were
290 positive cases with fever or history of fever and a positive RDT among children under 5
years in the district August–December, with an estimated total population of children of
7,000). District health records from 2010 showed a higher rate of about 0.1 per child per
month, or 0.5 per child per 5-month transmission season. We estimated that if 24 clusters
were randomised and each cluster included approximately 220 children, and assuming a coef-
ficient of variation of the incidence rate among clusters of 0.25, the trial would have 90%
power to detect a 50% reduction in incidence associated with SMC at the lower incidence rate
and 90% power for a 33% reduction at the higher rate.
The parasitological survey at the end of the transmission season was designed to have 80%
power to detect a reduction in mean Hb of 5 g/l in each age group (<5 years and 5–9 years),
and 80% power to detect a 40% reduction in parasite prevalence in both age groups combined.
For mean Hb concentration, data from a study in 2004 in Niakhar [9] gave a pooled estimate
of within-village standard deviation of 16 g/l, and an intra-class correlation of ρ = 0.04, in chil-
dren less than 5 years of age. Standard calculations give a sample size of N = 334 for an
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individually randomised study to have 80% power to detect a difference of 5 g/l if the SD is 16
g/l. The number required, allowing for clustering, is c�N�(1 − roh)/(c − N�ρ) for c clusters. This
gives a total sample size of 667 in each age group, or 1,334 in total. Allowing for non-response,
we therefore set the sample size at 70 children per village, 35 in each age group, to be selected
by simple random sampling from the census list in each village. For the prevalence of parasi-
taemia, this sample size would give 80% power to detect a 40% reduction (both age groups
combined) if the coefficient of variation between villages was 0.3 and the prevalence was 30%
in the control arm. For adherence surveys, it was estimated that about 300 children were
required to estimate the percentage adherence within ±6% if 80% of children adhered and
assuming a design effect of 2.
There were 3 analysis sets: Analysis of malaria incidence was by intention to treat, including all
children who were enrolled (all children in the correct age range who were present in the study
area at the initial census and were issued with a malaria ID card, regardless of the number of treat-
ments received; n = 4,546); analysis of survey outcomes included all children included in the end
of season survey (n = 1,424); and adherence was assessed in 318 children surveyed after cycle 4
and 462 after cycle 5. The time at risk for analysis of malaria incidence started on 27 July 2011 (the
first day of SMC) and ended on 31 December 2011, with observations censored at the date of
death or emigration if the child was known to have died or permanently emigrated. The timing of
malaria episodes was illustrated by plotting the Nelson–Aalen cumulative hazard (an estimate of
the mean number of episodes per child) over time in each group. Efficacy (percent reduction in
incidence associated with SMC) and the rate difference between the two study arms were calcu-
lated using a ratio estimator of the incidence rate in each group of the study, with stratification by
village type (served by case de santé or DSDOM). Interaction with age was tested using a t test
comparing between the study arms the within-cluster differences in the incidence rate between
age groups, as described by Cheung et al. [10].
Effects of SMC on the prevalence of parasitaemia, gametocyte carriage, mean Hb concentra-
tion, and prevalence of anaemia (Hb< 110 g/l) and severe anaemia (Hb< 60 g/l) were estimated
from the survey at the end of the transmission season using a survey ratio estimator (with the
associated standard errors in each group) and testing for interaction based on t tests comparing—
between trial arms—the between-age-group differences. The distribution of Hb concentration at
the end of the transmission season in each arm of the trial was plotted using a kernel density esti-
mator using the kdensity function of Stata (with the Epanechnikov kernel with a half-width of 6).
Analyses were performed using Stata version 14 (StataCorp, College Station, Texas).
Data management
Village registers that listed each child recorded in the census were printed for health workers
to record SMC administration and consultations for illness. All consultations for illness were
recorded, and the registers checked for completeness during weekly supervisory visits; at the
end of the study, the data were entered into a database in Dakar. SMC administration was
recorded in the registers, and similarly checked and entered. All data were entered into an
SQL database using an Access (Microsoft) front end. The accuracy of data input by each clerk
was monitored by checking a sample of data records, and all data entered by that clerk were
re-entered if errors were found. Automated checks for consistency and range errors were
done, and queries resolved before the dataset was locked for analysis.
Results
Twenty-four villages were randomised to receive SMC in addition to CCM for malaria or
CCM alone (Fig 3). The 2 groups were similar with respect to baseline characteristics
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(Table 1); the distance to the nearest health centre ranged from 4 km to 30 km, and insecti-
cide-treated bednet coverage was high. From July to November in 2010, the year before the
trial, from district health records there were a total of 1,238 cases of malaria in children under
5 years of age in the study villages, an incidence rate of 0.12 per child per month.
SMC delivery
A total of 10,222 SMC treatments were administered over 5 months. The percentage of chil-
dren treated each month was 89.8% (2,010/2,238) in cycle 1, 93.2% (2,080/2,232) in cycle 2,
92.4% (2,055/2,223) in cycle 3, 92.9% (2,065/2,222) in cycle 4, and 90.6% (2,012/2,221) in cycle
5 (Fig 3). On average, each month, 0.6% were excluded (due to illness or non-eligibility), and
0.1% refused. In villages with health huts, the mean number of children treated per day was 66,
Fig 3. Trial profile. SMC, seasonal malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1002762.g003
Table 1. Characteristics of the study villages at baseline.
Variable CCM SMC+CCM
Number of villages� 12 12
Total number of children aged 3–59 months 1,134 1,167
Total number of children aged 60–119 months 1,063 1,182
Mean (range) number of children aged 3–59 months per village 94.5 (39–239) 97.3 (29–183)
Mean (range) number of children aged 60–119 months per village 88.6 (30–257) 98.5 (28–205)
Mean (range) distance to the nearest health post or health centre 13 km (4–30) 17 km (5–21)
Percentage of children who slept under an ITN# 91% 94%
Mean malaria incidence/child/month the season before the trial† 0.12 0.11
�Six of the villages in each arm had CCM provided by a distributeur de soins à domicile (DSDOM), the other 6 had
CCM provided by an agent de santé communautaire (ASC) based at a health hut.
#Aged <5 years who slept under an ITN the night before the survey was conducted in July 2011.
†From July to November 2010.
CCM, community case management; ITN, insecticide-treated net; SMC, seasonal malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1002762.t001
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and the mean duration of SMC administration was 4 days per month. In villages with a
DSDOM, the mean number of children treated per day was 43, and the mean duration of SMC
administration was 3.7 days per month. Most villages adhered closely to the recommended
interval of 28 days between cycles (Fig 4), with the exception of one village that started cycle 4
a week early and another village that started cycle 5 a few days late.
Adherence
When adherence to the 3-day regimen was assessed in a sample of 318 children in October,
caregivers reported that 99.4% of children who received SMC had taken the first day’s doses
(SP and the first dose of AQ), 98.4% had taken the second daily dose of AQ, and 96.8% had
taken the third dose of AQ. Adherence was assessed again in 462 children in November, and
caregivers reported that drugs were administered to 462 (100%) on the first day, 455 (98%) on
the second day, and 447 (97%) on the third day. When caregivers were asked if the child swal-
lowed all of the medicine, caregivers reported that 116 (25%) children spat out some of the
medicine administered on the first day, 43/455 (9.5%) spat out some of the medicine on the
second day, and 34/447 (7.6%) on the third day. Three children started vomiting more than 1
hour after the dose on the second day. When caregivers were asked to show any leftover medi-
cation, 38 (8.2%) had some leftover tablets or half tablets on day 4.
Incidence of malaria
A total of 1,742 cases of malaria confirmed by RDT were reported between the date cycle 1
started (27 July 2011) and 31 December 2011 in children less than 10 years of age—1,472 cases
in the 12 villages with CCM alone and 270 cases in the villages with SMC, yielding incidence
rates of 128.3 and 22.0/1,000/month, respectively (Table 2). In the control villages, 797/1,472
(54%) cases were in children who were less than 5 years of age (their age at cycle 1), and 675
(46%) were in children aged 5–9 years; the incidence rates were 134.6 and 121.6/1,000/month
in each age group, respectively (Table 3). The number of episodes per child ranged from 0 to 5;
the mean number of episodes per child was 0.67 (Fig 5). In all, 43% of children had malaria at
least once, 17% had 2 or more episodes of malaria, and 3 children had 5 episodes of malaria
(Fig 6). In the SMC group, 145/270 cases (54%) were in children aged less than5 years, and
46% were in children aged 5–9 years; the incidence rates were 23.8 and 20.2/1,000/month in
each age group, respectively. The mean number of episodes per child was 0.11; 11% had
malaria at least once, and 0.8% had 2 or more episodes of malaria. The efficacy of SMC was
83% (95% CI 74%, 89%) in both age groups combined. The malaria incidence rate difference
between SMC and control villages was 110.8/1,000/month (95% CI 64.7, 156.8) in children
Fig 4. Timing of the 5 monthly cycles of seasonal malaria chemoprevention delivery in each village.
https://doi.org/10.1371/journal.pmed.1002762.g004
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under 5 years of age and 101.3 (95% CI 66.7, 136.0) in children 5–9 years of age, indicating
that SMC was associated with a reduction of over 100 malaria cases per 1,000 children in each
age group each month. The breakdown by calendar month (both age groups combined) is
shown in Table 4. Efficacy was similar in each month, but the incidence and hence reduction
in number of cases decreased, from about 180 cases reduced per 1,000 in each of the first 2
months, to a reduction of about 130 cases per 1,000 in the third month, 50 per 1,000 in the
fourth month, and 16 per 1,000 in the fifth month.
The prevalence of P. falciparum parasitaemia and gametocyte carriage at
the end of the transmission season
The prevalence of asexual P. falciparum infection in control villages at the end of the transmis-
sion season increased with children’s age, from about 15% in children under 2 years of age to
about 25% in children aged 4–9 years (Fig 7). The overall prevalence in the control villages was
21.5% (152/707 children surveyed positive by microscopy), compared to 5.7% (41/717) in the
SMC villages, a reduction of 73% (95% CI 52%, 85%). The reduction associated with SMC was
slightly greater in the age group 5–9 years (77%) compared to the group aged less than 5 years
(69%) (p-value for interaction p = 0.187). Gametocyte carriage (Fig 8) was 2.8% (20/707 chil-
dren) in control villages and 1.1% (8/717) in SMC villages, a reduction of 61% (95% CI −2.9%,
85%).
The prevalence of anaemia at the end of the transmission season
The mean Hb concentration in children aged less than 5 years was 94 g/l in the control villages
and 101 g/l in the SMC villages, an increase of 6.5 g/l (95% CI 2.0, 11) associated with SMC. In
the older children, the mean Hb concentration was 109 g/l in the control villages and 114 g/l in
the SMC villages, an increase of 5.2 g/l (95% CI 0.4, 9.9). A total of 19/707 (2.7%) children in
Table 2. Efficacy and impact of SMC against malaria, parasitaemia, gametocyte carriage, anaemia, and deaths: Both age groups combined.
Outcome CCM SMC+CCM Efficacy (95% CI) Difference (95% CI)
Malaria cases, rate/1,000 (number of cases/1,000s of person-months)� 128.3 (1,472/
11.48)
22.0 (270/
12.27)
83% (74%, 89%) 106.3 (66.9, 145.6), p< 0.001
Prevalence of parasitaemia†, percent (number positive/number sampled) 21.5% (152/707) 5.7% (41/717) 73% (52%, 85%) 15.8% (8.7%, 22.8%), p<
0.001
Gametocyte carriage†, percent (number positive/number sampled) 2.8% (20/707) 1.1% (8/717) 61% (−2.9%,
85%)
1.7% (0%, 3.4%), p = 0.05
Mean Hb, g/l† 101 107 5.9 (1.6, 10.2), p = 0.009
Anaemia (Hb < 110 g/l)† 63.1% 51.5% 18% (4.4%, 30%) 11.6% (3.0%, 20.2%), p =
0.010
Severe anaemia (Hb < 60 g/l)†, percent (number anaemic/number sampled) 2.7% (19/707) 1.3% (9/717) 53% (−21%, 82%) 1.4% (−0.25%, 3.1%), p =
0.093
Deaths from all causes, rate/1,000 (number of deaths/1,000s of person-
months)�
1.0 (12/11.48) 1.1 (14/12.27) −0.10 (−1.18, 0.99), p = 0.856
Children aged less than 10 years (aged 3–119 months at cycle 1). The coefficient of variation between villages after stratification was 0.37 for malaria incidence. The
intra-class correlation for parasite prevalence was 0.045 and for mean Hb concentration was 0.06. p-values from tests for interaction between age group and intervention
(tests of effect modification by age group): malaria incidence, p = 0.631; prevalence of parasitaemia, p = 0.187; gametocyte carriage, p = 0.360; mean Hb concentration, p
= 0.797; anaemia, p = 0.237; severe anaemia, p = 0.191.
�Confirmed cases or deaths per 1,000 child-months at risk (number of cases or deaths/1,000s of child-months).
†Measured at the end of the transmission season.
CCM, community case management; Hb, haemoglobin; SMC, seasonal malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1002762.t002
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Table 3. Efficacy and impact of SMC against malaria, parasitaemia, gametocyte carriage, anaemia, and deaths, in each age group.
Outcome CCM SMC+CCM Efficacy (95% CI) Difference‡ (95% CI)
Children <5 years (aged 3–59 months at cycle 1)?
Malaria cases, rate/1,000 (cases/1,000s of person-months)� 134.6 (797/5.92) 23.8 (145/6.10) 82% (71%, 89%) 110.8 (64.7, 156.8), p< 0.001
Prevalence of parasitaemia† 18% 5.7% 69% (42%, 83%) 12.5% (6.8%, 18.2%), p< 0.001
Gametocyte carriage† 3.5% 1.1% 69% (−2.1%, 91%) 2.45% (−0.6%, 5.5%), p = 0.105
Mean Hb, g/l† 94 101 7 (2, 11), p = 0.007
Anaemia (Hb < 110 g/l)† 77.4% 68.4% 12% (0.0%, 22%) 9.1% (0.6%, 17.5%), p = 0.037
Severe anaemia (Hb < 60 g/l)† 3.3% 0.81% 75% (13%, 93%) 2.5% (0.2%, 5.0%), p = 0.036
Deaths from all causes, rate/1,000 (deaths/1,000s of person-months)� 1.87 (11/5.92) 1.98 (12/6.10) −0.11 (−2.0, 1.8)
Children 5–9 years (aged 60–119 months at cycle 1)
Malaria cases, rate/1,000 (cases/1,000s of person-months)� 121.6 (675/5.55) 20.2 (125/6.17) 83% (76%, 89%) 101.3 (66.7, 136.0), p< 0.001
Prevalence of parasitaemia† 25% 5.8% 77% (53%, 89%) 19.3% (8.3%, 30.2%), p = 0.001
Gametocyte carriage† 2.1% 1.2% 44% (−115%, 86%) 0.9% (−1.0%, 2.8%), p = 0.327
Mean Hb, g/l† 109 114 5.2 (0.4, 9.9), p = 0.035
Anaemia (Hb < 110 g/l)† 47.5% 33.4% 30% (5.4%, 48%) 14.1% (3.1%, 25.0%), p = 0.014
Severe anaemia (Hb < 60 g/l)† 2.1% 1.7% 16% (−224%, 78%) 0.3% (−2.1%, 2.8%), p = 0.778
Deaths from all causes, rate/1,000 (deaths/1,000s of person-months)� 0.18 (1/5.55) 0.32 (2/6.17) −0.14 (−0.66, 0.37)
‡Difference: CCM − SMC+CCM.
�Confirmed cases or deaths per 1,000 child-months (number of cases or deaths/1,000s of child-months) for July–November 2011.
†Measured at the end of the transmission season.
CCM, community case management; Hb, haemoglobin; SMC, seasonal malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1002762.t003
Fig 5. The timing of RDT-confirmed malaria episodes in each age group, in SMC and control villages, for 5 months
from the SMC start date. The y-axis shows the Nelson–Aalen cumulative hazard, equal to the mean number of episodes
of malaria experienced per child from the start of the study up to the given time (in months since the date when cycle 1
started in SMC villages), in children in villages targeted with SMC and in the control villages. CCM, community case
management; RDT, rapid diagnostic test; SMC, seasonal malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1002762.g005
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the control villages had severe anaemia (Hb < 60 g/l), compared to 1.3% (9/717) in the SMC
group. There was weak evidence that SMC was associated with a greater reduction in severe
anaemia in the age group under 5 years (interaction p-value = 0.191). Among children aged
less than 5 years, 3.3% had Hb < 60 g/l in the control villages compared to 0.81% in the SMC
villages, a reduction of 75% (95% CI 13%, 93%). The distribution of Hb concentration in each
age group and intervention group is shown in Fig 9.
Adverse events
Twenty-six children were known to have died during the study: 12 deaths in the control vil-
lages were reported by village reporters, while in the SMC villages 8 deaths were reported by
village reporters and a further 6 were detected when the child’s absence during SMC cycles
was investigated by the study team. Twenty-three of the deaths were in children aged less than
Fig 6. The effect of SMC on the number of children who experienced multiple episodes of malaria during the
transmission season. The number of children who were treated for RDT-confirmed malaria 1, 2, 3, 4, or 5 times is
shown for children in each age group, in villages targeted with SMC and in control villages. CCM, community case
management; RDT, rapid diagnostic test; SMC, seasonal malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1002762.g006
Table 4. Efficacy of SMC and the number of malaria cases averted per 1,000 children, in each month.
Month Number of malaria cases/1,000/month Efficacy (95% CI) Rate difference per 1,000 (95% CI) p-Value
CCM SMC+CCM
1 203.9 25.5 87.5% (79.6%, 92.3%) 178.4 (121.3, 235.4) <0.001
2 223.9 42.1 81.2% (69.1%, 88.5%) 181.8 (117.4, 246.2) <0.001
3 162.9 34.5 78.8% (65.6%, 87.0%) 128.5 (72.7, 184.2) <0.001
4 61.0 10.6 82.6% (59.5%, 92.5%) 50.3 (14.9, 85.8) 0.007
5 17.8 2.1 88.0% (61.6%, 96.3%) 15.6 (−0.1, 31.3) 0.051
CCM, community case management; SMC, seasonal malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1002762.t004
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5 years, and 3 in children 5–9 years of age. The mortality rate ratio (SMC:control) was 1.1
(95% CI 0.4, 3.0). For the 12 deaths in control villages, the cause of death at verbal autopsy was
considered to be malaria (9 children), meningitis (1 child), pneumonia (1 child), or sepsis (1
child). For the 14 deaths in SMC villages, the cause of death was considered to be malaria (7
children), malaria and pneumonia (1 child), malaria and diarrhoea (1 child), diarrhoea (3 chil-
dren), acute respiratory infection (1 child), or sepsis (1 child). Sixteen of the 26 deaths
occurred at home, 8 occurred in the health post, 1 in the district health centre, and 1 while the
child was being transported to the health centre. Of the 14 deaths in SMC villages, the exact
date of death—and hence the timing of the death in relation to the start of the most recent
course of SMC—was available for 6 children. One of these children (whose death was consid-
ered to be due to malaria and pneumonia) had not received SMC; one died 26 days after SMC
(of malaria and diarrhoea), one 33 days after SMC (of diarrhoea), one 26 days after SMC (of
malaria), one 27 days after SMC (of sepsis), and one 9 days after SMC (of diarrhoea).
A total of 29 cases of suspected adverse drug reactions were reported by CHWs. Vomiting
was the most commonly reported symptom (11 cases). There was 1 case of rash on both arms
and chest, occurring 3 days after the child received the first dose of SMC in cycle 1 (this child
was excluded from further SMC). None of the adverse events was considered severe.
Accuracy of malaria RDTs
Blood films from 1,126 patients with a positive RDT and from 227 patients with a negative
RDT were examined by microscopy. RDT sensitivity, compared to microscopy, was 95%, and
specificity was 48% (Table 5). There was some evidence that specificity was higher in the SMC
Fig 7. The effect of SMC on the prevalence of parasitaemia. The prevalence of P. falciparum infection at the end of
the transmission season in each arm of the trial, by age group. CCM, community case management; SMC, seasonal
malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1002762.g007
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villages (63% compared to 42% in CCM villages, p = 0.054) and sensitivity lower (79% com-
pared to 97%, p = 0.037).
The prevalence of molecular markers of resistance to SMC drugs among
incident malaria cases
RDT-derived DNA from 240 incident malaria cases were typed, 110 from control villages and
130 from SMC villages (Table 6). About 40% of samples in each group carried both the
pfmdr1-86Y and -184Y mutation (38% in the control villages and 42% in the SMC villages).
Fig 8. The effect of SMC on the prevalence of gametocyte carriage: The prevalence of gametocyte carriage at the
end of the transmission season in each arm of the trial, by age group. There were no carriers aged 8–9 years in the
CCM group. CCM, community case management; SMC, seasonal malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1002762.g008
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Fig 9. The effect of SMC on anaemia. The distribution of haemoglobin concentrations measured at the end of the transmission season is shown, for each age
group of children, in villages with SMC and in control villages, using a kernel density estimator to plot the smoothed distribution of concentrations in each
group. The left-hand plot shows children aged less than 5 years, the middle plot children 5–9 years of age. In the right-hand plot the 2 age groups have been
superimposed for comparison. CCM, community case management; SMC, seasonal malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1002762.g009
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The pfdhfr mutations (51I, 59R, and 108N) and pfdhps-437A occurred more frequently in the
cases from the SMC villages (Table 6). The pfdhps-540E mutation was found in 2 samples, 1
from a control village and 1 from an SMC village. These 2 samples carried only the wild type at
pfdhps codons 436, 437, and 613. Mutations at pfmdr1-1246 were not typed in the samples
from malaria cases.
The prevalence of molecular markers of resistance to SMC drugs among
children surveyed at the end of the transmission season
In the survey at the end of the transmission season, 182 positive samples were typed, 140 from
control villages and 42 from SMC villages (Table 7). The pfmdr1-86Y mutation was found in
Table 5. Comparison of RDT results with microscopy, in a sample of RDT-positive and RDT-negative patients.
RDT outcome CCM alone SMC+CCM
Microscopy Total Microscopy Total
Positive Negative Positive Negative
RDT+ 836 153 989 96 41 137
RDT− 22 111 133 25 69 94
CCM, community case management; RDT, rapid diagnostic test; SMC, seasonal malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1002762.t005
Table 6. Prevalence of molecular variants associated with resistance to sulfadoxine-pyrimethamine and amodiaquine, in samples from malaria cases.
Variant CCM SMC+CCM Difference (95%
CI)
p-Value
Number positive/number
typed
Prevalence (95%
CI)
Number positive/number
typed
Prevalence (95%
CI)
pfmdr1-86Y 77/110 0.70 (0.55, 0.85) 76/123 0.62 (0.49, 0.74) −0.08 (−0.28, 0.11) 0.394
pfmdr1-184Y 57/110 0.52 (0.46, 0.57) 69/123 0.56 (0.50, 0.62) 0.04 (−0.04, 0.12) 0.280
pfdhfr-51I 34/110 0.31 (0.19, 0.43) 54/130 0.42 (0.34, 0.49) 0.11 (−0.03, 0.25) 0.131
pfdhfr-59R 28/110 0.25 (0.14, 0.36) 59/130 0.45 (0.34, 0.57) 0.20 (0.04, 0.36) 0.018
pfdhfr-108N 28/110 0.25 (0.16, 0.35) 66/130 0.51 (0.38, 0.63) 0.25 (0.10, 0.41) 0.003
pfdhps-436A 33/110 0.30 (0.18, 0.42) 59/130 0.45 (0.38, 0.53) 0.15 (0.02, 0.29) 0.031
pfdhps-437A 43/110 0.39 (0.29, 0.49) 46/130 0.35 (0.29, 0.42) −0.04 (−0.15, 0.08) 0.519
pfdhps-540E 1/70 0.01 (−0.01, 0.04) 1/118 0.01 (−0.01, 0.02) −0.01 (−0.04, 0.03) 0.721
pfdhps-613S 2/70 0.03 (−0.01, 0.07) 3/118 0.03 (−0.01, 0.06) 0.00 (−0.05, 0.05) 0.899
pfmdr1-86Y+184Y 42/110 0.38 (0.28, 0.48) 52/123 0.42 (0.35, 0.49) 0.04 (−0.08, 0.16) 0.486
pfdhfr-51I+59R
+108N�
19/108 0.18 (0.08, 0.27) 48/127 0.38 (0.30, 0.46) 0.20 (0.08, 0.32) 0.003
pfdhps haplotypes 431, 436, 437, 540, 613#
IAAKAA 14/68 0.21 (0.10, 0.31) 26/113 0.23 (0.19, 0.27) 0.02 (−0.09, 0.14) 0.664
IAGKAA 9/68 0.13 (0.04, 0.22) 23/113 0.20 (0.11, 0.29) 0.07 (−0.06, 0.20) 0.254
IAGKAS 2/68 0.03 (−0.01, 0.07) 2/113 0.02 (0.00, 0.04) −0.01 (−0.06, 0.03) 0.590
ISAKAA 10/68 0.15 (0.07, 0.22) 13/113 0.12 (0.05, 0.18) −0.03 (−0.13, 0.07) 0.521
ISGEAA 1/68 0.01 (−0.02, 0.04) 1/113 0.01 (−0.01, 0.03) −0.01 (−0.04, 0.03) 0.726
ISGKAA 37/68 0.54 (0.43, 0.66) 54/113 0.48 (0.40, 0.56) −0.07 (−0.21, 0.07) 0.332
ISGKAS 0/68 0.00 (0.00, 0.00) 1/113 0.01 (−0.01, 0.03) 0.01 (−0.01, 0.03) 0.289
�Five samples mixed for 2 codons were excluded.
#Seven samples mixed for 2 codons and 52 samples with missing data were excluded.
CCM, community case management; SMC, seasonal malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1002762.t006
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only 11 samples, and only 2 samples (both in the control group) carried both the 86Y and
184Y mutations. The pfmdr1-1246Y mutation was found in 1 sample, in the control group.
This sample carried the 184Y mutation but not the 86Y mutation. The pfdhfr triple mutation
51I+59R+108N was more common in the end of season survey than among the clinical cases,
but the prevalence was similar in both intervention groups (55% in the control group and 66%
in the SMC group in the end of season survey, compared to 18% and 38%, respectively, in the
clinical cases). The pfdhps-540 mutation was not identified in the survey samples.
Discussion
In this cluster randomised trial of SMC with CCM for malaria in children aged less than 10
years delivered over 5 months in the Saraya district of south-east Senegal, we showed that
SMC was associated with a reduction of more than 100 malaria cases per 1,000 children per
month both in children aged less than 5 years of age and in children aged 5–9 years, compared
to CCM alone, and with a reduction in the prevalence of anaemia and malaria parasitaemia at
the end of the transmission season in both age groups. SMC was well tolerated over this period,
which is longer than studied previously [3] and longer than is currently used in national SMC
programmes, where SMC is provided for 3 or 4 months [1]. A relatively small reduction in the
Table 7. Prevalence of molecular variants associated with resistance to sulfadoxine-pyrimethamine and amodiaquine, from survey samples at the end of the trans-
mission season.
Variant CCM SMC+CCM Difference (95% CI) p-Value
Number positive/number
typed
Prevalence (95% CI) Number positive/number
typed
Prevalence (95% CI)
pfmdr1-86Y 5/140 0.04 (0.00, 0.07) 6/42 0.14 (0.04, 0.24) 0.11 (0.00, 0.21) 0.044
pfmdr1-184Y 96/140 0.69 (0.62, 0.75) 24/42 0.57 (0.49, 0.65) −0.11 (−0.22, −0.01) 0.037
pfmdr1-1246Y 1/140 0.01 (−0.01, 0.02) 0/42 0.00 (0.00, 0.00) −0.01 (−0.02, 0.01) 0.297
pfdhfr-51I 91/140 0.65 (0.56, 0.74) 21/30 0.70 (0.62, 0.78) 0.05 (−0.07, 0.17) 0.393
pfdhfr-59R 92/140 0.66 (0.60, 0.72) 20/30 0.67 (0.53, 0.80) 0.01 (−0.14, 0.16) 0.895
pfdhfr-108N 100/140 0.71 (0.65, 0.77) 22/30 0.73 (0.63, 0.84) 0.02 (−0.10, 0.14) 0.738
pfdhps-436A 45/140 0.32 (0.22, 0.42) 11/42 0.26 (0.11, 0.41) −0.06 (−0.24, 0.12) 0.505
pfdhps-437A 65/140 0.46 (0.34, 0.59) 19/42 0.45 (0.22, 0.68) −0.01 (−0.27, 0.25) 0.926
pfdhps-613S 3/140 0.02 (0.00, 0.05) 4/42 0.10 (0.04, 0.15) 0.07 (0.02, 0.13) 0.016
pfmdr1 haplotypes 86, 184, 1246
YYD 2/139 0.01 (0.00, 0.03) 0/42 0.00 (0.00, 0.00) −0.01 (−0.03, 0.01) 0.148
YND 3/139 0.02 (0.00, 0.05) 6/42 0.14 (0.04, 0.24) 0.12 (0.02, 0.22) 0.024
NYY 1/139 0.01 (0.00, 0.02) 0/42 0.00 (0.00, 0.00) −0.01 (−0.02, 0.01) 0.296
NYD 93/139 0.67 (0.60, 0.73) 24/42 0.57 (0.49, 0.65) −0.10 (−0.20, 0.01) 0.067
NND 47/139 0.34 (0.27, 0.41) 13/42 0.31 (0.20, 0.42) −0.03 (−0.16, 0.10) 0.658
pfdhfr-51I+59R
+108N
68/123 0.55 (0.46, 0.64) 19/29 0.66 (0.52, 0.79) 0.10 (−0.06, 0.26) 0.194
pfdhps haplotypes 431, 436, 437, 540, 581, 613
IAAKAA 28/132 0.21 (0.14, 0.28) 6/42 0.17 (0.06, 0.27) −0.05 (−0.17, 0.08) 0.467
IAGKAA 8/132 0.06 (0.02, 0.10) 1/42 0.02 (−0.02, 0.07) −0.04 (−0.10, 0.03) 0.239
IAGKAS 1/132 0.01 (−0.01, 0.02) 3/42 0.07 (0.01, 0.14) 0.06 (0.00, 0.13) 0.062
ISAKAA 34/132 0.26 (0.17, 0.35) 12/42 0.29 (0.13, 0.45) 0.03 (−0.16, 0.21) 0.753
ISGKAA 72/132 0.55 (0.42, 0.67) 19/42 0.45 (0.28, 0.63) −0.09 (−0.31, 0.13) 0.386
ISGKAS 1/132 0.01 (−0.01, 0.02) 1/42 0.02 (−0.02, 0.07) 0.02 (−0.03, 0.06) 0.469
CCM, community case management; SMC, seasonal malaria chemoprevention.
https://doi.org/10.1371/journal.pmed.1002762.t007
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number of cases was shown in the fifth month of treatment, but because incidence was already
very high at the time of the first cycle, it is possible that if cycle 1 had started earlier, in early
July, the fifth treatment might have had more impact. Delivery of SMC by resident CHWs,
who were also providing CCM for malaria, achieved high coverage each month and ensured
that children with symptomatic malaria were promptly treated with artemether-lumefantrine.
The findings of this study are consistent with those of Cisse´ et al. [3], who showed that SMC
was effective in children aged less than 10 years. That study was done in an area with a shorter
transmission season and lower transmission intensity than the present study. Our study shows
that in an area with more intense malaria transmission, with a significant burden of malaria in
older children, these children benefitted from being included in SMC. In the previous study,
SMC given to children up to the age of 10 years was associated with a reduction in transmis-
sion, as shown by reduced incidence in those who did not receive SMC (children above the
age for SMC and adults) in the areas where SMC was used. In our study we were not able to
measure indirect effects on transmission, but it is likely that indirect effects contributed to the
results of our study. The relative magnitude of indirect effects may be expected to be somewhat
lower in areas of higher transmission intensity.
Several previous studies have combined intermittent preventive treatment and CCM for
malaria [11–14]. Two studies in Ghana—a pilot study [11] and a cluster randomised trial
[12]—evaluated intermittent preventive treatment of children aged less than 5 years combined
with presumptive treatment of fever cases and showed that the combined strategy reduced the
number of presumptive cases. A study in The Gambia showed that village health workers
could successfully combine testing and treatment of malaria with administration of SMC, but
the malaria incidence was too low to determine any impact of SMC [13]. In a pilot study in
Senegal, CHWs providing home management for malaria were trained to deliver SMC for 2
months; this study showed a reduction in malaria incidence associated with SMC and a reduc-
tion in prevalence at the end of the transmission season [14].
Combining SMC delivery with CCM increases the promptness of treatment of break-
through cases, and has other potential advantages including opportunities for catch-up of
missed SMC doses and reduced costs of delivery for both interventions [7]. During SMC
cycles, children who are unwell are not given SMC drugs but are referred for testing with an
RDT so that they can be given ACT if they have malaria [1]. In villages without access to test-
ing and treatment for malaria locally, children found to be unwell during SMC visits are
referred to the nearest health facility. In Mali, SMC has been delivered in communities at fixed
points by mobile teams able to administer SMC and to test febrile children with an RDT and
treat with an ACT if the test was positive [15]. It is not known whether this approach can be
taken door to door effectively.
Our study had a number of limitations. One limitation was that we were not able to show
an impact of SMC on mortality or on severe malaria. The study was not designed to measure
an effect on mortality, and it is possible that some deaths may have been missed because addi-
tional deaths not reported by village reporters were detected in the SMC arm of the trial when
children who were absent at SMC cycles were investigated. We collected data on all admissions
to Saraya Hospital during the year of the study in order to determine the age distribution and
seasonal pattern of malaria hospital admissions. These data showed that there was a similar
number of malaria admissions in the group aged 5–9 years as in the age group under 5 years,
the majority occurring during the 5 months from July to November, suggesting that SMC tar-
geting children under the age of 10 years for 5 months might be needed. In the control villages
in our study, 17% of children had malaria on 2 or more occasions, and 3 children had malaria
5 times in 5 months, while only 0.8% of children in SMC villages had more than 1 malaria epi-
sode. Children who have more episodes of clinical malaria are more likely to develop severe
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disease that leads to hospital admission [16]. Although we could not demonstrate an impact of
SMC on severe disease, the impact on uncomplicated malaria suggests that the intervention
might also be effective in preventing severe cases, as has been observed in earlier trials [17,18].
Another limitation of the study was that we were not able to obtain malaria smears for all
malaria cases: CHWs had been trained to make blood films but not all were able to do this con-
sistently. Parasitological confirmation of malaria therefore relied on RDTs, which may have
resulted in false positives. Although the study was not designed to measure RDT characteris-
tics, we noted that when the accuracy of diagnosis by RDT was compared with microscopy,
specificity was low, as has been observed in other high-transmission settings [19] due to persis-
tence of HRP2 protein. Specificity was higher in the SMC villages, reflecting the lower expo-
sure to infection. RDT sensitivity was somewhat lower in the SMC villages, possibly due to
lower parasite densities.
SMC was well tolerated; however, we were not able to monitor effects of repeated treat-
ments on biochemical parameters and haematological parameters (other than Hb concentra-
tion at the end of the transmission season).
CCM linked to SMC ensures that breakthrough malaria cases can be promptly treated with
artemether-lumefantrine. We found that the frequency of the pfmdr1 mutations 86Y and
184Y, associated with AQ resistance, was lower in children carrying P. falciparum parasites at
the end of the transmission season than in samples taken from children presenting with
malaria during the study. It is known that treatment with artemether-lumefantrine selects for
wild-type alleles at these loci [20]. Prompt treatment of malaria cases in SMC areas may there-
fore act to limit selection for AQ resistance by SMC.
Our results suggest that the impact of SMC programmes could be substantially increased by
including older children. The detailed distribution of malaria cases by age is often not available
to health managers, due to the fact that reporting of malaria cases to national health manage-
ment information systems is in broad age groups (under 5 years, and 5 years and above; in
some countries, 3 categories are used: under 5 years, 5–14 years, and 15 years and above). Indi-
vidual patient data may need to be obtained from hospitals to determine the appropriate upper
age limit for SMC programmes. SMC was well tolerated in our study, but further studies
should assess the safety of repeated SMC treatments if given for longer periods. SMC can act as
a screening programme, but in areas with poor access to healthcare, referral of sick children
may be problematic. Combining SMC with CCM services in such areas should be further eval-
uated. Other household members could also be screened for malaria, especially slightly older
children who have stopped receiving SMC.
This cluster randomised trial of SMC in children aged less than 10 years in a high-transmis-
sion area in the south-east of Senegal showed that high coverage of SMC could be achieved
over 5 months and that the treatments were well tolerated, were associated with a similar num-
ber of reductions in malaria episodes in the age groups under 5 years and 5–9 years, and
reduced the prevalence of parasitaemia and anaemia in both age groups. Combining SMC
with CCM ensured children with malaria were promptly treated with artemether-
lumefantrine.
Twelve countries now have SMC programmes, reaching about 17 million children in 2017
[21]. Despite the challenges of delivering SMC, many countries have achieved high coverage
and have seen substantial reductions in malaria cases. This success has led national malaria
control programmes to consider whether older children should be included in SMC pro-
grammes, and whether more than 4 SMC cycles can be given, which would allow expansion of
the geographical area targeted by SMC programmes to include communities living in areas
where the transmission season is longer. The findings of this study indicate that SMC could be
administered over a longer period and/or to a wider age group. The SMC strategy used in this
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study could be adapted, based on local epidemiology, to increase the impact of SMC on
malaria.
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Chimioprévention du paludisme saisonnier combinée à la prise en charge communautaire du 
paludisme chez les enfants de moins de 10 ans pendant 5 mois dans le sud du Sénégal: essai clinique 
randomisé en grappes. 
 
Abstract  
 
Contexte: 
La chimioprévention du paludisme saisonnier (CPS) est recommandée dans le sahel chez les enfants 
de moins de 5 ans, pendant 4 mois. Il peut être approprié d’inclure des enfants plus âgés et de les 
protéger plus de 4 mois. Nous avons évalué l'efficacité de la CPS avec la sulfadoxine-pyriméthamine 
plus amodiaquine pendant 5 mois chez les enfants de moins de 10 ans dans le district de Saraya au 
sud du Sénégal en 2011. 
 
Méthodes et résultats: 
Vingt-quatre villages avec 2301 enfants âgés de 3 à 59 mois et 2 245 âgés de 5 à 9 ans, ont été 
randomisés pour recevoir la CPS et/ou une prise en charge communautaire du paludisme (PECC). Dans 
tous les villages, des agents de santé communautaires (ASC) ont été formés pour traiter les cas de 
paludisme avec une combinaison à base de dérivés d’artémisinine après un test de diagnostic rapide 
(TDR). Dans les villages CPS, les ASC ont administré la CPS aux enfants âgés de 3 mois à 9 ans, une fois 
par mois pendant 5 mois. Les enfants ont été suivis de juillet à décembre. Le critère d'évaluation 
principal était le paludisme (fièvre ou antécédents de fièvre avec un TDR positif). La prévalence de 
l'anémie et de la parasitémie ont été mesurées lors d'une enquête transversale à la fin de la saison de 
transmission. Les marqueurs moléculaires de résistance du Plasmodium aux médicaments de la CPS 
ont été analysés chez les cas incidents de paludisme et chez des enfants porteurs asymptomatiques 
pendant  l’enquête. La CPS a été bien tolérée avec aucun évènement indésirable noté. Il y a eu 1470 
cas de paludisme confirmés par TDR dans les villages témoins et 270 dans les villages CPS. La 
différence de taux chez les enfants de moins de 5 ans était de 110,8 (IC 95% : 64,7- 156,8; p <0,001) et 
chez les enfants de 5 à 9 ans de 101,3 /1000 /mois (IC 95%: 66,7 -136,0; p <0,001). Le taux moyen 
d'hémoglobine était plus élevée dans les villages CPS que dans les villages témoins, de 0,65 g/dl (IC 
95%: 0,20- 1,1; p = 0,007) chez les enfants de moins de 5 ans et de 0,52 g/dL. (IC 95% 0,04-0,99; p = 
0,035) chez les enfants de 5 à 9 ans. La prévalence de la parasitémie était de 18% chez les enfants de 
moins de 5 ans et 25% chez les enfants de 5 à 9 ans dans les villages témoins, et de 5,7% et 5,8% 
respectivement dans ces deux groupes d'âge dans les villages CPS, une différence de prévalence de 
12,5% (IC 95%: 6,8%- 18,2%; p <0,001) chez les moins de 5 ans et de 19,3% (IC 95%: 8,3%-30,2%; p 
<0,001) chez les 5 à 9 ans. La mutation Pfdhps-540E associée à une résistance clinique à la 
sulfadoxine-pyriméthamine a été retrouvée dans 0,8% des cas incidents de paludisme, mais non 
retrouvée lors de l'enquête. Douze enfants sont décédés dans le groupe témoin et 14 dans le groupe 
CPS, soit une différence de taux de 0,096/ 1 000 enfants-mois, IC à 95%: 0,99-1,18; p = 0,895. Une 
limite a été que nous n'étions pas en mesure d'obtenir des frottis sanguins pour tous les cas suspects 
de paludisme, et que nous nous en remettions aux TDR pour le diagnostic, lesquels pouvaient inclure 
des faux positifs. 
 
Conclusion: La CPS chez les enfants de moins de 10 ans pendant 5 mois a été faisable, bien tolérée, 
très efficace pour prévenir les accès palustres et réduire la prévalence de la parasitémie et de 
l'anémie. La CPS combinée à la PEEC  a obtenu une couverture élevée, assurant que les enfants 
souffrant d’accès palustres soient rapidement traités avec de l'artéméther-luméfantrine et réduisant 
ainsi la charge de travail des ASC. 
